公开(公告)号：US20180298093A1

公开(公告)日：2018-10-18

申请号：US15912494

申请日：2018-03-05

Applicant: AbbVie Inc.

Inventor： Boris Labkovsky ,  Tariq Ghayur ,  Georgeen Gaza-Bulseco ,  Pratibha Mishra ,  Subramanya Hegde ,  Sudha Krishnan

IPC: C07K16/24 ,  C07K16/00

Abstract: Provided are glycoengineered populations of Fc domain-containing binding proteins with a reduced anti-drug immune response (ADA). Also provided are methods of treating disease using such compositions, and methods and host for making such compositions.

公开(公告)号：US20170232000A9

公开(公告)日：2017-08-17

申请号：US15136582

申请日：2016-04-22

Applicant: AbbVie Inc.

Inventor： Steven Elmore ,  Andrew Souers ,  Lichun Wang ,  Tariq Ghayur ,  Stuart J. Perper

IPC: A61K31/5377 ,  A61K31/496

CPC classification number: A61K31/5377 ,  A61K31/496

Abstract: This invention pertains to methods of treating systemic lupus erythematosus and Sjogren's Syndrome with compounds that selectively inhibit the activity of Bcl-2 anti-apoptotic proteins. Specifically, the current invention is directed to treatment with compounds that selectively inhibit the activity of Bcl-2 proteins, with a lesser affinity for inhibiting the activity of other BCL-2 family proteins, including Bcl-XL

公开(公告)号：US20160235760A1

公开(公告)日：2016-08-18

申请号：US15136582

申请日：2016-04-22

Applicant: AbbVie Inc.

Inventor： Steven Elmore ,  Andrew Souers ,  Lichun Wang ,  Tariq Ghayur ,  Stuart J. Perper

IPC: A61K31/5377 ,  A61K31/496

CPC classification number: A61K31/5377 ,  A61K31/496

Abstract: This invention pertains to methods of treating systemic lupus erythematosus and Sjogren's Syndrome with compounds that selectively inhibit the activity of Bcl-2 anti-apoptotic proteins. Specifically, the current invention is directed to treatment with compounds that selectively inhibit the activity of Bcl-2 proteins, with a lesser affinity for inhibiting the activity of other BCL-2 family proteins, including Bcl-XL

Abstract translation: 本发明涉及用选择性抑制Bcl-2抗凋亡蛋白活性的化合物治疗系统性红斑狼疮和干燥综合征的方法。 具体地说，本发明涉及用选择性抑制Bcl-2蛋白活性的化合物治疗，对抑制其它BCL-2家族蛋白（包括Bcl-XL）的活性具有较小的亲和力

公开(公告)号：US20160145334A1

公开(公告)日：2016-05-26

申请号：US14989532

申请日：2016-01-06

Applicant: AbbVie Deutschland GmbH & Co. KG ,  AbbVie Inc.

Inventor： Mario Mezler ,  Achim Moeller ,  Reinhold Mueller ,  Bernhard K. Mueller ,  Tariq Ghayur ,  Eve H. Barlow ,  Martin Schmidt ,  Axel Meyer ,  Nicole Teusch

IPC: C07K16/28 ,  A61K39/395

CPC classification number: C07K16/28 ,  A61K39/3955 ,  A61K2039/505 ,  C07H21/00 ,  C07K16/2863 ,  C07K2317/14 ,  C07K2317/34 ,  C07K2317/41 ,  C07K2317/56 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  Y02A50/466

Abstract: The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind to the Nogo-66 receptor. Specifically, these antibodies have the ability to inhibit the binding of the natural ligand of the Nogo-66 receptor and neutralize the Nogo-66 receptor. These antibodies or portions thereof of the invention are useful for detecting NgR and for inhibiting NgR activity, for example in a human suffering from a disorder in which NgR or Nogo-66 activity is detrimental.

Abstract translation: 本发明涉及结合Nogo-66受体的分离的蛋白质，特别是单克隆抗体。 具体地说，这些抗体具有抑制Nogo-66受体的天然配体结合并中和Nogo-66受体的能力。 本发明的这些抗体或其部分可用于检测NgR和抑制NgR活性，例如在患有NgR或Nogo-66活性有害的病症的人中。

公开(公告)号：US09303085B2

公开(公告)日：2016-04-05

申请号：US14104991

申请日：2013-12-12

Applicant: AbbVie, Inc.

Inventor： Chengbin Wu ,  Dominic J. Ambrosi ,  Chung-ming Hsieh ,  Tariq Ghayur

IPC: A61K38/00 ,  C07K16/24 ,  C07K14/545 ,  A61K39/395 ,  A61K47/48 ,  G01N33/68 ,  A61K45/06 ,  A61K9/00

CPC classification number: C07K16/245 ,  A61K9/0014 ,  A61K9/0019 ,  A61K9/0031 ,  A61K9/0034 ,  A61K9/0043 ,  A61K9/0053 ,  A61K9/006 ,  A61K9/007 ,  A61K9/0085 ,  A61K38/00 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/6879 ,  C07K14/545 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/64 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/6869 ,  G01N2333/545 ,  G01N2800/00 ,  Y02A50/385 ,  Y02A50/401 ,  Y02A50/409 ,  Y02A50/412 ,  Y02A50/463 ,  Y02A50/478 ,  Y02A50/481

Abstract: Proteins that bind IL-1α and IL-1β are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1α and IL-1β in cells, tissues, samples, and compositions.

Abstract translation: 结合IL-1α和IL-1和bgr的蛋白质 描述其用于治疗，预防和诊断IL-1相关疾病和用于检测IL-1α和IL-1和bgr的组合物和方法中的用途; 在细胞，组织，样品和组合物中。

公开(公告)号：US20160046730A1

公开(公告)日：2016-02-18

申请号：US14811909

申请日：2015-07-29

Applicant: AbbVie Inc.

Inventor： Tariq Ghayur ,  Junjian Liu

IPC: C07K16/46 ,  A61K39/395 ,  C07K16/28 ,  A61K45/06 ,  C07K16/22 ,  A61K47/48 ,  G01N33/68

CPC classification number: C07K16/468 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/6845 ,  C07K16/22 ,  C07K16/2863 ,  C07K16/2887 ,  C07K16/2896 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/64 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/6872

Abstract: Engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease are provided.

Abstract translation: 提供了工程化的多价和多特异性结合蛋白，制备方法，特别是其在预防，诊断和/或治疗疾病中的用途。

公开(公告)号：US20150315283A1

公开(公告)日：2015-11-05

申请号：US14687392

申请日：2015-04-15

Applicant: AbbVie Inc.

Inventor： Tariq Ghayur ,  Peter C. Isakson ,  Lisa M. Olson ,  Chengbin Wu ,  Margaret Hugunin ,  Rajesh V. Kamath ,  Carolyn A. Cuff ,  Hamish J. Allen

IPC: C07K16/28 ,  C07K16/22 ,  G01N33/68 ,  A61K39/395 ,  A61K45/06 ,  C07K16/24 ,  A61K47/48

CPC classification number: C07K16/2887 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/6845 ,  A61K2039/505 ,  A61K2039/70 ,  C07K16/22 ,  C07K16/241 ,  C07K16/244 ,  C07K16/245 ,  C07K16/247 ,  C07K16/248 ,  C07K16/2866 ,  C07K16/468 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/64 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/6869 ,  G01N2333/545 ,  Y02A50/386 ,  Y02A50/41 ,  Y02A50/412 ,  Y02A50/58

Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.

公开(公告)号：US20150183867A1

公开(公告)日：2015-07-02

申请号：US14644524

申请日：2015-03-11

Applicant: AbbVie Inc.

Inventor： Tariq Ghayur ,  Alfred Hahn ,  Bernhard Mueller

IPC: C07K16/24 ,  G01N33/68 ,  A61K47/48 ,  A61K45/06 ,  C07K16/18 ,  A61K39/395

CPC classification number: C07K16/2869 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/6843 ,  A61K47/6845 ,  A61K47/6849 ,  C07K16/18 ,  C07K16/22 ,  C07K16/241 ,  C07K16/244 ,  C07K16/245 ,  C07K16/248 ,  C07K16/28 ,  C07K16/2803 ,  C07K16/2863 ,  C07K16/2887 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/53 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/626 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/6863 ,  G01N2333/525 ,  Y02A50/386 ,  Y02A50/41 ,  Y02A50/412 ,  Y02A50/58

Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.

公开(公告)号：US20150150870A1

公开(公告)日：2015-06-04

申请号：US14535070

申请日：2014-11-06

Applicant: AbbVie Inc.

Inventor： Steven Elmore ,  Andrew Souers ,  Lichun Wang ,  Tariq Ghayur ,  Stuart J. Perper

IPC: A61K31/496 ,  A61K31/5377

CPC classification number: A61K31/5377 ,  A61K31/496

Abstract: This invention pertains to methods of treating systemic lupus erythematosus and Sjogren's Syndrome with compounds that selectively inhibit the activity of Bcl-2 anti-apoptotic proteins. Specifically, the current invention is directed to treatment with compounds that selectively inhibit the activity of Bcl-2 proteins, with a lesser affinity for inhibiting the activity of other BCL-2 family proteins, including Bcl-xL.

Abstract translation: 本发明涉及用选择性抑制Bcl-2抗凋亡蛋白活性的化合物治疗系统性红斑狼疮和干燥综合征的方法。 具体地，本发明涉及用选择性抑制Bcl-2蛋白活性的化合物治疗，对抑制其它BCL-2家族蛋白（包括Bcl-xL）活性的亲和性较小。

公开(公告)号：US20150139988A1

公开(公告)日：2015-05-21

申请号：US14542281

申请日：2014-11-14

Applicant: AbbVie, Inc.

Inventor： Boris Labkovsky ,  Tariq Ghayur ,  Georgeen Gaza-Bulseco ,  Pratibha Mishra ,  Subramanya Hedge ,  Sudha Krishnan

IPC: C07K16/24

CPC classification number: C07K16/241 ,  A61K2039/505 ,  C07K16/00 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/30 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/77 ,  Y02A50/386

Abstract: Provided are glycoengineered populations of Fc domain-containing binding proteins with a reduced anti-drug immune response (ADA). Also provided are methods of treating disease using such compositions, and methods and host for making such compositions.

Abstract translation: 提供具有减少的抗药物免疫应答（ADA）的具有Fc结构域的结合蛋白的糖工程化群体。 还提供了使用这种组合物治疗疾病的方法，以及制备这种组合物的方法和宿主。